Skip to content

IBRX - ImmunityBio, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchI

Immunitybio Inc

IBRX · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

I

IBRXImmunitybio Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $12.43
52-wk low: $1.95
Prev close: $7.69
Mkt cap: $8.31B
Beta: 0.13
P/S: 50.1x

Smart money

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$773.9M

DS
D.E. Shaw
Q2 2026 13F
$101.1M
position
TS
Two Sigma
Q2 2026 13F

Earnings

Reported Aug 4, 2026

Earnings came in $0.01 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $8.3B

Valuation

P/S50.12

Quality

Operating margin-120.4%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: IBRX
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $8.31B
Beta: 0.13

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

-120.4%

ROE

+0.0%

$97.2M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$48.9M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for IBRX

No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.08+$0.01

-$0.09 expected

Next report

What the street expects next

EPS expected

-$0.05

-$0.09 to $0.00

Revenue expected

$59.2M

4 analysts

Last 30 days

1up1down

Split both ways

Estimate drift

+0.02

Change in 30 days

0.0%

ROA-30.5%

Growth

Beta0.13